Saudi Central Bank Has $3.02 Million Stake in Becton, Dickinson and Company $BDX

Saudi Central Bank lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 89.6% in the second quarter, HoldingsChannel reports. The institutional investor owned 19,951 shares of the medical instruments supplier’s stock after buying an additional 9,431 shares during the period. Saudi Central Bank’s holdings in Becton, Dickinson and Company were worth $3,019,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the last quarter. Empowered Funds LLC boosted its holdings in Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after purchasing an additional 1,354 shares during the period. United Bank grew its holdings in shares of Becton, Dickinson and Company by 23.9% during the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after purchasing an additional 993 shares in the last quarter. Marshall Wace LLP grew its stake in Becton, Dickinson and Company by 365.1% during the second quarter. Marshall Wace LLP now owns 31,876 shares of the medical instruments supplier’s stock worth $5,491,000 after buying an additional 25,022 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 34.7% during the 2nd quarter. NewEdge Advisors LLC now owns 23,501 shares of the medical instruments supplier’s stock worth $4,048,000 after acquiring an additional 6,058 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,105 shares of company stock worth $1,590,208 in the last three months. Corporate insiders own 0.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BDX. Jefferies Financial Group reissued a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, August 6th. TD Cowen increased their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Finally, Bank of America upped their price target on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $187.67.

Becton, Dickinson and Company Trading Up 0.0%

Shares of NYSE BDX opened at $184.78 on Tuesday. The firm has a 50 day moving average price of $170.65 and a two-hundred day moving average price of $160.63. The stock has a market cap of $50.91 billion, a P/E ratio of 55.66, a price-to-earnings-growth ratio of 13.02 and a beta of 0.21. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $193.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the prior year, the business posted $3.68 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 126.51%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.